2. Search Result
Search Result
Results for "

Levodopa

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Peptides

4

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-N0304
    L-DOPA
    Maximum Cited Publications
    35 Publications Verification

    Levodopa; 3,4-Dihydroxyphenylalanine

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA
  • HY-N0304R
    L-DOPA (Standard)
    1 Publications Verification

    Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)

    		 Reference Standards Dopamine Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA (Standard)
  • HY-14859
    Dipraglurant

    ADX48621

    		 mGluR Neurological Disease
    Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC50 of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Dipraglurant
  • HY-116016
    Etilevodopa

    L-DOPA ethyl ester; Levodopa ethyl ester

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa
  • HY-W011963
    Melevodopa hydrochloride

    		Dopamine Receptor Neurological Disease
    Melevodopa hydrochloride is an effervescent Levodopa (HY-N0304) prodrug. Levodopa is an orally active metabolic precursor of neurotransmitters dopamine and has anti-allodynic effects and the potential for Parkinson's disease
    Melevodopa hydrochloride
  • HY-N0304A
    L-DOPA sodium
    Maximum Cited Publications
    35 Publications Verification

    Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .
    L-DOPA sodium
  • HY-N0304S
    L-DOPA-d6

    Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA-d6
  • HY-109131
    Foscarbidopa

    ABBV-951; Carbidopa 4′-monophosphate

    		 Aryl Hydrocarbon Receptor Drug Metabolite Neurological Disease
    Foscarbidopa (ABBV-951; Carbidopa 4′-monophosphate) is an inhibitory prodrug targeting peripheral aromatic L-amino acid decarboxylase. Foscarbidopa is hydrolyzed into Carbidopa (HY-B0311) by phosphatases in vivo to suppress peripheral metabolism of levodopa and elevate brain delivery of levodopa. Foscarbidopa can be used for the research of Parkinson’s disease and advanced Parkinson’s disease .
    Foscarbidopa
  • HY-132392S
    L-DOPA-2,5,6-d3

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain .
    L-DOPA-2,5,6-d3
  • HY-N0304S2
    L-DOPA-13C
    1 Publications Verification

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA- 13C is the 13C labeled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA-13C
  • HY-N0304S1
    L-DOPA-13C6

    Levodopa-13C6; 3,4-Dihydroxyphenylalanine-13C6

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA- 13C6 is the 13C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-DOPA-13C6
  • HY-116016A
    Etilevodopa hydrochloride

    L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa hydrochloride
  • HY-CE01682
    Levodopa-CoA

    Levodopa-coenzyme A

    		 Biochemical Assay Reagents Metabolic Disease
    Levodopa-CoA (Levodopa-coenzyme A) is a coenzyme A derivative .
    Levodopa-CoA
  • HY-116016AR
    Etilevodopa hydrochloride (Standard)

    L-DOPA ethyl ester hydrochloride (Standard); Levodopa ethyl ester hydrochloride (Standard)

    		 Reference Standards Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (hydrochloride) (Standard) is the analytical standard of Etilevodopa (hydrochloride). This product is intended for research and analytical applications. Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].
    Etilevodopa hydrochloride (Standard)
  • HY-122278
    Melevodopa

    		Dopamine Receptor Neurological Disease
    Melevodopa is an effervescent levodopa (HY-N0304) prodrug. Levodopa is an orally active metabolic precursor of neurotransmitters dopamine and has anti-allodynic effects and the potential for Parkinson's disease .
    Melevodopa
  • HY-116016R
    Etilevodopa (Standard)

    L-DOPA ethyl ester (Standard); Levodopa ethyl ester (Standard)

    		 Reference Standards Dopamine Receptor Drug Metabolite Neurological Disease
    Chlorbenside (Standard) is the analytical standard of Chlorbenside. This product is intended for research and analytical applications. Chlorbenside is an organochlorine pesticide. Chlorbenside targets organism such as mites and ticks and possesses efficient ovicidal and larvicidal activities .
    Etilevodopa (Standard)
  • HY-B0311D
    Carbidopa hydrochloride

    (S)-(-)-Carbidopa hydrochloride

    		 Aryl Hydrocarbon Receptor Cancer
    Carbidopa hydrochloride ((S)-(-)-Carbidopa hydrochloride) is a drug used to inhibit Parkinson's disease, which has the activity of inhibiting the peripheral metabolism of levodopa. Carbidopa hydrochloride can increase the proportion of peripheral levodopa penetrating the blood-brain barrier, thereby enhancing its effect on the central nervous system. Carbidopa hydrochloride has also been found to be an aryl hydrocarbon receptor (AhR) ligand with anticancer activity, which can inhibit the growth of pancreatic cancer cells and tumors. The selective AhR regulation properties of carbidopa hydrochloride provide potential prospects for its clinical application .
    Carbidopa hydrochloride
  • HY-P11504
    Fmoc-Lys-Gly-Dopa-OH

    		Biochemical Assay Reagents Others
    Fmoc-Lys-Gly-Dopa-OH is a tripeptide. Fmoc-Lys-Gly-Dopa-OH forms coacervates in aqueous solution via phase separation. Fmoc-Lys-Gly-Dopa-OH coacervates, with the assistance of Fe 3+, provide a viable material to engineer the surface of mammalian cells .
    Fmoc-Lys-Gly-Dopa-OH
  • HY-N18690
    Mucuna pruriens extract

    		Others Neurological Disease
    Mucuna pruriens extract, derived from the seeds of the Mucuna pruriens plant, the primary active compound in Mucuna pruriens is L-dopa (levodopa), a precursor to the neurotransmitter dopamine, which contributes to its neuroprotective and mood-enhancing effects.
    Mucuna pruriens extract
  • HY-167899
    PXT-012253

    		mGluR Neurological Disease
    PXT-012253 is a positron emission tomography (PET) ligand for mGluR4, as it binds to an allosteric site on mGluR4. PXT-012253 can be utilized in researches related to Parkinson's disease and levodopa-induced dyskinesia .
    PXT-012253
  • HY-101008
    3-MPPI

    		Adrenergic Receptor G protein-coupled Bile Acid Receptor 1 Cardiovascular Disease Neurological Disease
    3-MPPI is a GPCR ligand with high selectivity for α1-adrenergic receptor, with a Ki value of 0.21 nM for α1-adrenergic receptor and 50 nM for 5-HT1A receptor. 3-MPPI modulates the α1-adrenergic receptor signaling cascade. 3-MPPI is applicable to research related to hypertension, stress-induced anxiety-like behavioral responses, and levodopa-induced dyskinesia .
    3-MPPI
  • HY-182638
    CPL500036

    		Phosphodiesterase (PDE) mAChR Potassium Channel Neurological Disease
    CPL500036 is an orally active, blood-brain barrier permeable phosphodiesterase 10A (PDE10A) inhibitor with IC50 values of 1 nM (Reference 1) and 35 nM (Reference 2). CPL500036 acts as a negative allosteric modulator of the M2 muscarinic receptor with an IC50 of 9.2 μM. CPL500036 alters cyclic nucleotide levels in basal ganglia circuits, inhibits the hydrolysis of cAMP and cGMP, and suppresses hERG potassium channel tail currents. CPL500036 induces catalepsy in rats and reverses injury-induced contralateral forelimb use impairment. CPL500036 can be used in research related to schizophrenia, Parkinson's disease, and levodopa-induced dyskinesia .
    CPL500036
  • HY-18654A
    ADX88178 TFA

    		mGluR Neurological Disease
    ADX88178 TFA is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 TFA modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 TFA reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 TFA can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease .
    ADX88178 TFA

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: